These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15608694)

  • 1. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
    Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
    Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
    MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM
    Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
    MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
    Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
    Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
    Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
    MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
    Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL; Earel JK; Griffith TS
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
    Izeradjene K; Douglas L; Delaney AB; Houghton JA
    Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
    Nesterov A; Nikrad M; Johnson T; Kraft AS
    Cancer Res; 2004 Jun; 64(11):3922-7. PubMed ID: 15173003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
    Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
    Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Singh TR; Shankar S; Srivastava RK
    Oncogene; 2005 Jul; 24(29):4609-23. PubMed ID: 15897906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
    J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
    J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
    Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
    Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.